Myocardial Infarction (Death Of The Heart Muscle) Stem Cell Treatment Three Times Better Than Anticipated
“..8.5 percent improvement just four months following the reintroduction of stem cells and 12 percent after one year.”
these results hold up in future studies, I believe this could be the
biggest revolution in cardiovascular medicine in my lifetime.”
By Dell Hill
incredible stem cell research results are being documented at hospitals
around the world. Today’s report suggests that damaged heart tissue
can be repaired, rather than left for “dead”, by use of the patients own
Our report comes from Diagnostic and Interventional Cardiology.
failure patients with a previous myocardial infarction showed an
average of 12 percent improvement one year following an investigative
treatment that infused them with their own stem cells. The results
triple the 4 percent improvement average the researchers projected for
the Phase I trial.
of the trial have been published in The Lancet and concurrently
presented at the American Heart Association Scientific Sessions in
Orlando, Fla. They are the first report of administering subjects’ own
cardiac stem cells in humans. Previous studies have used stem cells
harvested from bone marrow.
research team, led by Roberto Bolli, M.D., of the University of
Louisville and Piero Anversa, M.D., at Brigham and Women’s
Hospital/Harvard Medical School in Boston, conducted the SCIPIO trial;
SCIPIO is an acronym for “Cardiac Stem Cells in Patients with Ischemic
16 trial patients were diagnosed with heart failure following a
myocardial infarction and had a left ventricular ejection fraction
(LVEF) of 40 percent or lower. LVEF is a standard measure of the heart’s
pumping capability; it measures how much blood is ejected from the left
ventricle during a heartbeat. The normal LVEF is 50 percent or higher.
investigators harvested cardiac stem cells from the patients during
coronary artery bypass surgery conducted at Jewish Hospital in
Louisville. Cardiac stem cells are referred to as “c-kit positive” cells
because they express the c-kit protein on their surface. They were
purified in Anversa’s lab in Boston and allowed to grow. Once an
adequate number of stem cells were produced – about one million –
Bolli’s team in Louisville reintroduced them into the region of the
patient’s heart that had been scarred by the infarction.
designing the trial, Bolli and Anversa examined data from previous
studies of bone marrow-derived stem cells and projected an average
improvement in LVEF of 4-5 percent for all patients. They witnessed an
8.5 percent improvement just four months following the reintroduction of
stem cells and 12 percent after one year.
researchers also conducted magnetic resonance imaging (MRI) studies on
the patients’ hearts and saw the size of the scarred regions had
decreased – a result that seemingly begins to disprove the long-held
belief that once scarring occurs, the heart tissue is forever dead.
– who is lead author of the Lancet article and presenter of the data at
the scientific sessions – says the adult stem cell protocol could
become one of the greatest advancements in cardiac treatment in a
results are striking,” Bolli said. “While we do not yet know why the
improvement occurs, we have no doubt now that ejection fraction
increased and scarring decreased. If these results hold up in future
studies, I believe this could be the biggest revolution in
cardiovascular medicine in my lifetime.”
I invite you to read the entire article by clicking right here.